MAP2K7 and uveal melanoma: In a publication by Faião-Flores et al., a panel of GNAQ/GNA11-mutant uveal melanoma cell lines (including OMM1 cells) was characterized with respect to the MEK inhibitor response (i.e. trametinib) [34].